The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | SURPASS-ET: switching to ropeginterferon alfa-2b improves hematologic control in ET
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses updated findings from the Phase III SURPASS-ET study (NCT04285086) evaluating patients with essential thrombocythemia (ET) who switched from anagrelide to ropeginterferon alfa-2b. Dr Masarova highlights improvements in hematologic responses and blood count control following the switch, supporting the role of ropeginterferon alfa-2b as an important treatment option for patients requiring second-line therapy. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This EHA Congress, we presented an update of the SURPASS-ET study, which was the second line compared to anagrelide in patients with essential thrombocythemia trying ropeginterferon, which is injectable versus oral anagrelide. And now these data show the switch. So people that were initially randomized to anagrelide and then were eligible to switch to ropeg interferon, how would they perform after the switch, so basically what we have seen is that there was a significant improvement in response in terms of control of the blood counts once people switched to ropeginterferon, even within the initial three months, so there was actually nice achievements of ELN response as well as individual control of platelets and white cells in more than double the amount of patients initially switching from anagrelide...
This EHA Congress, we presented an update of the SURPASS-ET study, which was the second line compared to anagrelide in patients with essential thrombocythemia trying ropeginterferon, which is injectable versus oral anagrelide. And now these data show the switch. So people that were initially randomized to anagrelide and then were eligible to switch to ropeg interferon, how would they perform after the switch, so basically what we have seen is that there was a significant improvement in response in terms of control of the blood counts once people switched to ropeginterferon, even within the initial three months, so there was actually nice achievements of ELN response as well as individual control of platelets and white cells in more than double the amount of patients initially switching from anagrelide. So that’s kind of encouraging and confirming the data from the first analysis of the SURPASS-ET study, and hopefully will be further evaluated in the two-year or longer assessments of the safety and efficacy. But for now, this is quite encouraging. I would say it is established as a standard after frontline failures for ET patients, particularly patients that would have more proliferative or needed more control of the counts and safety profile will be updated a little bit but overall looks very positive.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
